Chief Executive Officer
Jonathan Adam Barash is an accomplished Chief Executive Officer with 25 years of global experience as an entrepreneur and executive leader. Throughout his career, he has demonstrated exceptional ability in…
The OncoFirm Diagnostics Advisory Board is composed of leading experts in oncology, molecular diagnostics, regulatory affairs, clinical medicine, and biotechnology commercialization. This distinguished group provides strategic guidance and scientific oversight as we advance the development and global deployment of our rapid cancer screening technologies.
Our advisors bring deep experience from academia, healthcare systems, diagnostic innovation, and public health policy—ensuring that our products are clinically relevant, regulatory-ready, and impactful across diverse healthcare settings. With their insights, we are driving innovation that empowers early cancer detection and improves outcomes for patients worldwide.
Watch our team coming together!
Jonathan Adam Barash is an accomplished Chief Executive Officer with 25 years of global experience as an entrepreneur and executive leader. Throughout his career, he has demonstrated exceptional ability in…
A team of researchers led by scientists that has developed fluorescent lateral flow test (FLFT) for our early detection cancer rapid tests. A fluorescent lateral flow test (FLFT) is a…
A distinguished member of a Scientific Advisory Council, which has made significant contributions to cancer immunotherapy, particularly in ovarian cancer. His research focuses on identifying tumor antigens and developing immunotherapeutic…
AbulKalam M. Shamsuddin, M.B.,B.S., Ph.D., served as Professor of Pathology at the University of Maryland School of Medicine in Baltimore, MD, for over 43 years, Senior Scientist at National Cancer…